RFA-CA-23-028: Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $250,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 30, 2024.
From the official notice on Grants.gov, last changed October 1, 2024. Checked November 7, 2026.
- Award ceiling$250,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUG3 / UH3
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$333,625
- Typical project length3 years
- UG3, Exploratory/Developmental Phase I Cooperative Agreement. The first phase of a phased cooperative agreement. Moving on to the UH3 phase depends on meeting agreed milestones. Other open UG3 notices.
- UH3, Exploratory/Developmental Cooperative Agreement Phase II. The second phase of a phased cooperative agreement, usually following a UG3 or UH2 phase. Other open UH3 notices.
Projects funded under RFA-CA-23-028 were run by National Cancer Institute (NCI, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-23-028 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-CA-25-013 | October 1, 2024 | Closed June 13, 2025 | Closed |
Key dates
| Posted | March 23, 2023 |
|---|---|
| Deadline | September 30, 2024 |
| Archived by Grants.gov | October 30, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $333,625; it allows up to $250,000 per award.
- Most of the program's money (66% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The overall goal of this UG3/UH3 Exploratory/Developmental phased initiative is to support the discovery and development of novel natural products that are safe, nontoxic, and efficacious for cancer interception and prevention. 1. Purpose of UG3: Select clinically relevant targets and develop and validate assays for bioactivity as well as toxicity screening 2. Purpose of UH3 phase: Screening libraries, structure elucidation, full-scale characterization, efficacy testing, and development of the screened agents.
Funded under RFA-CA-23-028 so far
NIH funded 6 projects under RFA-CA-23-028 in fiscal 2024 to 2026, at 6 institutions. The median yearly award was $333,625.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Discovery of novel natural TEAD inhibitors for the chemoprevention of liver tumors | University of Hawaii at Hilo | 2026 | $322,891 |
| Discovery and Development of Natural Products for Interception of CRC | University of Oklahoma HLTH Sciences Ctr | 2026 | $303,875 |
| Nautral products for targeting Skp2 in cancer interception | University of California-Irvine | 2026 | $333,625 |
| Developing ribosome biogenesis inhibitors for the prevention of cancer | UT Southwestern Medical Center | 2026 | $292,886 |
| Discovery of Natural Products and Natural Product Derivatives as Inhibitors of KLK6 to Prevent the Progression of Preneoplastic Ductal Pancreatic Cancer | Cold Spring Harbor Laboratory | 2026 | $398,400 |
| Developing Natural Products to Target IL-8 Signaling and Intercept Progression of Barrett’s Esophagus to Esophageal Adenocarcinoma | University of Michigan at Ann Arbor | 2025 | $323,226 |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-23-028 still open?
No. It closed on September 30, 2024.
Who can apply for Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)?
Closed September 30, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $250,000 each.
Who has been funded under RFA-CA-23-028?
NIH RePORTER lists 6 projects funded under RFA-CA-23-028 in fiscal 2024 to 2026, at 6 institutions. The most were at University of Hawaii at Hilo, University of Oklahoma HLTH Sciences Ctr, University of California-Irvine.
Who has won Cancer Cause and Prevention Research grants before?
The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New York. The program made 2,517 awards worth $3.6 billion in that time.
Similar open grants
- Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required)
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
- Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
- Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
- NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)